Home / Ingredients / Long-chain omega-3 fatty acids / fish oil
Evidence reviewed: 2026-10-02
Established triglyceride-lowering effect at appropriate EPA/DHA doses; broader cardiovascular outcomes are context-dependent.
Long-chain omega-3 supplements can lower triglycerides. NIH ODS notes that high-dose prescription omega-3 therapy is used for elevated triglycerides, while evidence for other cardiovascular endpoints varies by population and dose.
Clinical effects depend heavily on actual EPA/DHA intake, not simply the presence of fish oil.
FDA and EFSA have considered combined EPA+DHA intakes up to about 5 g/day generally safe when used as recommended, though individual risks and medication interactions still matter.
V-OMEGA3 currently lists Wild Alaska salmon oil but does not publish EPA and DHA amounts on the manufacturer page. A triglyceride-lowering claim cannot be inferred from the ingredient list alone.
Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (Dose-response meta-analysis of randomized controlled trials; PMID 37264945)
Population/scope: Adults in randomized trials of EPA+DHA supplementation
Evidence scope: Triglycerides and other lipid outcomes
Finding: EPA+DHA supplementation showed a dose-responsive triglyceride-lowering effect; lipid effects varied by outcome and dose.
Limitations: Lipid changes do not establish broad cardiovascular-event prevention, and results depend on actual EPA/DHA intake rather than generic fish-oil presence.
Directness: Relevant human evidence · verified 2026-10-02
Dose-related meta-analysis for Omega-3 fatty acids supplementation on major adverse cardiovascular events (Meta-analysis of long-term randomized controlled trials; PMID 35290840)
Population/scope: 19 randomized trials; 97,709 participants
Evidence scope: All-cause mortality, cardiac death, myocardial infarction, and stroke
Finding: Omega-3 supplementation was not consistently associated with lower major cardiovascular outcomes across dose categories.
Limitations: Results varied by dose, formulation, prevention setting, statin use, and trial design; findings should not be generalized to triglyceride treatment.
Directness: Relevant human evidence · verified 2026-10-02
Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.
For informational purposes only; not individualized medical advice.